Clinical characteristics in type 1 diabetic patients in the cross-sectional surveys
| . | 1997 . | 2004 . | P . |
|---|---|---|---|
| Age (years) | 38.6 ± 13.0 (9,424) | 41.6 ± 13.5 (13,612) | <0.001 |
| Women/men (%) | 45.6/54.4 (9,424) | 45.5/54.5 (13,612) | NS |
| Age of debut (years) | 15.4 ± 7.6 (9,424) | 15.5 ± 7.7 (13,612) | NS |
| Duration (years) | 23.1 ± 13.4 (9,424) | 26.1 ± 14.1 (13,612) | <0.01 |
| A1C (%) | 8.16 ± 1.27 (9,424) | 7.96 ± 1.22 (13,612) | <0.001 |
| A1C <7.0% (%) | 17.4 (9,424) | 21.2 (13,612) | <0.001 |
| A1C <8.0% (%) | 49.1 (9,424) | 56.2 (13,612) | <0.001 |
| A1C <9.0% (%) | 76.7 (9,424) | 82.0 (13,612) | <0.001 |
| Systolic BP (mmHg) | 130.0 ± 17.6 (9,424) | 128.7 ± 16.8 (13,612) | <0.001 |
| Diastolic BP (mmHg) | 75.0 ± 9.0 (9,424) | 73.6 ± 9.0 (13,612) | <0.001 |
| BP <130/80 mmHg (%) | 35.2 (9,424) | 39.3 (13,612) | <0.001 |
| BP <140/85 mmHg (%) | 77.1 (9,424) | 80.6 (13,612) | <0.001 |
| Antihypertensive drugs (%) | 23.0 (9,424) | 33.9 (13,612) | <0.001 |
| BP <130/80 mmHg (%) | 17.4 (2,170) | 20.0 (4,610) | <0.01 |
| BP ≤140/85 mmHg (%) | 56.1 (2,170) | 62.6 (4,610) | <0.001 |
| Hypertension (%) | 42.4 (9,424) | 45.5 (13,612) | <0.001 |
| Antihypertensive drugs (%) | 54.3 (3.997) | 74.4 (6,193) | <0.001 |
| BP <130/80 mmHg (%) | 9.4 (3.997) | 14.9 (6,193) | <0.001 |
| BMI women (kg/m2) | 24.9 ± 3.9 (9,424) | 25.2 ± 4.3 (13,612) | <0.001 |
| BMI men (kg/m2) | 25.0 ± 3.2 (9,424) | 25.4 ± 3.4 (13,612) | <0.001 |
| BMI <25 kg/m2 (%) | 56.2 (9,424) | 52.3 (13,612) | <0.001 |
| BMI ≥30 kg/m2 (%) | 8.1 (9,424) | 10.5 (13,612) | <0.001 |
| Smokers, aged <30 years, women (%) | 15.4 (9,424) | 16.0 (13,612) | NS |
| Smokers, aged <30 years, men (%) | 9.0 (9,424) | 9.3 (13,612) | NS |
| Smokers, aged 30–59 years (%) | 17.0 (9,424) | 14.3 (13,612) | <0.001 |
| Smokers, aged >60 years (%) | 8.8 (9,424) | 9.0 (13,612) | NS |
| . | 1997 . | 2004 . | P . |
|---|---|---|---|
| Age (years) | 38.6 ± 13.0 (9,424) | 41.6 ± 13.5 (13,612) | <0.001 |
| Women/men (%) | 45.6/54.4 (9,424) | 45.5/54.5 (13,612) | NS |
| Age of debut (years) | 15.4 ± 7.6 (9,424) | 15.5 ± 7.7 (13,612) | NS |
| Duration (years) | 23.1 ± 13.4 (9,424) | 26.1 ± 14.1 (13,612) | <0.01 |
| A1C (%) | 8.16 ± 1.27 (9,424) | 7.96 ± 1.22 (13,612) | <0.001 |
| A1C <7.0% (%) | 17.4 (9,424) | 21.2 (13,612) | <0.001 |
| A1C <8.0% (%) | 49.1 (9,424) | 56.2 (13,612) | <0.001 |
| A1C <9.0% (%) | 76.7 (9,424) | 82.0 (13,612) | <0.001 |
| Systolic BP (mmHg) | 130.0 ± 17.6 (9,424) | 128.7 ± 16.8 (13,612) | <0.001 |
| Diastolic BP (mmHg) | 75.0 ± 9.0 (9,424) | 73.6 ± 9.0 (13,612) | <0.001 |
| BP <130/80 mmHg (%) | 35.2 (9,424) | 39.3 (13,612) | <0.001 |
| BP <140/85 mmHg (%) | 77.1 (9,424) | 80.6 (13,612) | <0.001 |
| Antihypertensive drugs (%) | 23.0 (9,424) | 33.9 (13,612) | <0.001 |
| BP <130/80 mmHg (%) | 17.4 (2,170) | 20.0 (4,610) | <0.01 |
| BP ≤140/85 mmHg (%) | 56.1 (2,170) | 62.6 (4,610) | <0.001 |
| Hypertension (%) | 42.4 (9,424) | 45.5 (13,612) | <0.001 |
| Antihypertensive drugs (%) | 54.3 (3.997) | 74.4 (6,193) | <0.001 |
| BP <130/80 mmHg (%) | 9.4 (3.997) | 14.9 (6,193) | <0.001 |
| BMI women (kg/m2) | 24.9 ± 3.9 (9,424) | 25.2 ± 4.3 (13,612) | <0.001 |
| BMI men (kg/m2) | 25.0 ± 3.2 (9,424) | 25.4 ± 3.4 (13,612) | <0.001 |
| BMI <25 kg/m2 (%) | 56.2 (9,424) | 52.3 (13,612) | <0.001 |
| BMI ≥30 kg/m2 (%) | 8.1 (9,424) | 10.5 (13,612) | <0.001 |
| Smokers, aged <30 years, women (%) | 15.4 (9,424) | 16.0 (13,612) | NS |
| Smokers, aged <30 years, men (%) | 9.0 (9,424) | 9.3 (13,612) | NS |
| Smokers, aged 30–59 years (%) | 17.0 (9,424) | 14.3 (13,612) | <0.001 |
| Smokers, aged >60 years (%) | 8.8 (9,424) | 9.0 (13,612) | NS |
| . | 2002 . | 2004 . | P . |
|---|---|---|---|
| Total cholesterol (mmol/l) | 4.93 ± 0.91 (6,804) | 4.78 ± 0.89 (10,933) | <0.001 |
| Triglycerides (mmol/l) | 1.12 ± 0.58 (6,804) | 1.08 ± 0.57 (10,933) | <0.01 |
| HDL cholesterol (mmol/l) | 1.61 ± 0.47 (6,804) | 1.62 ± 0.50 (10,933) | NS |
| LDL cholesterol (mmol/l) | 2.82 ± 0.80 (6,804) | 2.67 ± 0.78 (10,933) | <0.001 |
| Lipid-lowering drugs (%) | 20.5 (10,114) | 24.4 (13,091) | <0.001 |
| Total cholesterol <5.0 (%) | 49.9 (1,474) | 58.8 (2,738) | <0.001 |
| Total cholesterol <4.5 (%) | 27.7 (1,474) | 37.7 (2,738) | <0.001 |
| Triglycerides <1.7 (%) | 75.9 (1,474) | 80.9 (2,738) | <0.001 |
| HDL cholesterol ≥1.0 men/≥1.3 women (%) | 87.5 (1,474) | 87.8 (2,738) | NS |
| LDL cholesterol <2.5 (%) | 38.3 (1,474) | 48.1 (2,738) | <0.001 |
| ASA, all patients (%) | 11.9 (7,332) | 16.8 (11,980) | <0.001 |
| ASA, BP-treated patients (%) | 29.7 (2,320) | 39.1 (4,098) | <0.001 |
| ASA, lipid-treated patients (%) | 37.6 (1,445) | 46.3 (2,949) | <0.001 |
| Eye control last 2 years (%) | 88.8 (9,716) | 93.5 (12,713) | <0.001 |
| Foot control last year (%) | 89.7 (8,009) | 92.5 (11,895) | <0.001 |
| . | 2002 . | 2004 . | P . |
|---|---|---|---|
| Total cholesterol (mmol/l) | 4.93 ± 0.91 (6,804) | 4.78 ± 0.89 (10,933) | <0.001 |
| Triglycerides (mmol/l) | 1.12 ± 0.58 (6,804) | 1.08 ± 0.57 (10,933) | <0.01 |
| HDL cholesterol (mmol/l) | 1.61 ± 0.47 (6,804) | 1.62 ± 0.50 (10,933) | NS |
| LDL cholesterol (mmol/l) | 2.82 ± 0.80 (6,804) | 2.67 ± 0.78 (10,933) | <0.001 |
| Lipid-lowering drugs (%) | 20.5 (10,114) | 24.4 (13,091) | <0.001 |
| Total cholesterol <5.0 (%) | 49.9 (1,474) | 58.8 (2,738) | <0.001 |
| Total cholesterol <4.5 (%) | 27.7 (1,474) | 37.7 (2,738) | <0.001 |
| Triglycerides <1.7 (%) | 75.9 (1,474) | 80.9 (2,738) | <0.001 |
| HDL cholesterol ≥1.0 men/≥1.3 women (%) | 87.5 (1,474) | 87.8 (2,738) | NS |
| LDL cholesterol <2.5 (%) | 38.3 (1,474) | 48.1 (2,738) | <0.001 |
| ASA, all patients (%) | 11.9 (7,332) | 16.8 (11,980) | <0.001 |
| ASA, BP-treated patients (%) | 29.7 (2,320) | 39.1 (4,098) | <0.001 |
| ASA, lipid-treated patients (%) | 37.6 (1,445) | 46.3 (2,949) | <0.001 |
| Eye control last 2 years (%) | 88.8 (9,716) | 93.5 (12,713) | <0.001 |
| Foot control last year (%) | 89.7 (8,009) | 92.5 (11,895) | <0.001 |
Data are means ± SD values (n) or frequencies (n). Significance levels were adjusted for age and sex. ASA, aspirin; BP, blood pressure.